Results 81 to 90 of about 1,158 (177)

Teduglutide Promotes Epithelial Tight Junction Pore Function in Murine Short Bowel Syndrome to Alleviate Intestinal Insufficiency

, 2020
Background!#!In short bowel syndrome, epithelial surface loss results in impaired nutrient absorption and may lead to intestinal insufficiency or intestinal failure. Nucleotide oligomerization domain 2 (Nod2) dysfunction predisposes to the development of
Bastian, Manuela, Reiner, Johannes, Lamprecht, Georg, Berlin, Peggy, Schäffler, Holger, Witte, Maria, Bannert, Karen, Vollmar, Brigitte, Jaster, Robert, Wobar, Jakob   +9 more
core   +1 more source

Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome [PDF]

, 2016
ObjectiveTo determine safety and pharmacodynamics/efficacy of teduglutide in children with intestinal failure associated with short bowel syndrome (SBS-IF).Study designThis 12-week, open-label study enrolled patients aged 1-17 years with SBS-IF who ...
Horslen, Simon, Teitelbaum, Daniel H., Thompson, John, Youssef, Nader N., Nichol, Peter F., Mercer, David F., Cole, Conrad R., Merritt, Russell J., Lim, Joel D., Hill, Susan, Sigurdsson, Luther, Corkins, Mark R., Cohran, Valeria C., Duggan, Christopher, Li, Benjamin, Kocoshis, Samuel A., Vaughan, Juliana F., Carter, Beth A., Venick, Robert S., Dimmitt, Reed A., Vanderpool, Charles   +20 more
core   +1 more source

Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure

, 2012
Teduglutide, a glucagon-like peptide 2 analogue, might restore intestinal structural and functional integrity by promoting growth of the mucosa and reducing gastric emptying and secretion.
Seidner, Douglas L., Joelsson, Bo, O'Keefe, Stephen J. D., Jeppesen, Palle B., Messing, Bernard, Pertkiewicz, Marek, Heinze, Hartmut, Forbes, Alastair, Iyer, Kishore   +8 more
core   +1 more source

Characteristics associated with response to teduglutide in pediatric short bowel syndrome-associated intestinal failure: Post hoc analysis of open-label long-term extension trials

Intestinal Failure
Background: Teduglutide can reduce dependence on parenteral nutrition and/or intravenous fluids (PN/IV) in children with short bowel syndrome-associated intestinal failure (SBS-IF).
Susan Hill, Beth Carter, Valeria Cohran, Samuel Kocoshis, Pradeep Nazarey, Ian Robinson, Brian Terreri, Robert Venick, Paul W. Wales, Danielle Wendel   +9 more
doaj   +1 more source

Treatment of adult short bowel syndrome patients with teduglutide

, 2012
INTRODUCTION: Parenteral support is lifesaving in short bowel syndrome patients with intestinal failure (SBS-IF), who are unable to compensate for their malabsorption by metabolic or pharmacologic adaptation.
Holst, Jens Juul, Nørholk, Lærke Marijke, Jeppesen, Palle Bekker   +2 more
core   +1 more source

A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment

Bioactive Materials
Current treatments for inflammatory bowel disease (IBD) treatment consist of anti-inflammatory products. In this study, we sought to induce the physiological secretion of glucagon-like peptide 2, a peptide with intestinal growth-promoting activity, via ...
Valentina Marotti, Yining Xu, Cécilia Bohns Michalowski, Wunan Zhang, Inês Domingues, Hafsa Ameraoui, Tom G. Moreels, Pieter Baatsen, Matthias Van Hul, Giulio G. Muccioli, Patrice D. Cani, Mireille Alhouayek, Alessio Malfanti, Ana Beloqui   +13 more
doaj   +1 more source

Therapeutic role of enterohormones in short bowel syndrome

Clinical Nutrition Open Science
Short bowel syndrome-associated chronic intestinal failure is the leading benign cause of long-term dependence on parenteral support in adults. Beyond the loss of absorptive surface area, intestinal resection profoundly modifies entero-hormonal signaling,
Lea Alioui, Palle Bekker Jeppesen, Tim Vanuytsel, Astrid Verbiest, Francisca Joly   +4 more
doaj   +1 more source

Real-world experience of teduglutide for the treatment of short bowel syndrome-associated intestinal failure

Patients with short bowel syndrome-associated intestinal failure (SBS-IF) require parenteral nutrition and/or intravenous fluids (PN/IV); however, long-term dependence can lead to complications.
Binion, David G, Gao, Emily, Swallow, Elyse, Zhao, Vivian M, Ziegler, Thomas R, Kang, Zoey, Kim, Dong Wook, Beck, Kendall R, Byers, Patricia M, Jiang, Jeanne, Cheng, Mu, Chen, Lily, Pham, Angela K, Greatsinger, Ali   +13 more
core   +1 more source

Tissular growth factors profile after teduglutide administration on an animal model of intestinal anastomosis

, 2018
Background: Teduglutide is an enterotrophic analogue of glucagon-like peptide-2, with an indirect and poorly understood mechanism of action, approved for the rehabilitation of short-bowel syndrome.
Abrantes,Ana-M., Botelho,M.-Filomena, Seiça,Raquel, Gonçalves,Ana-C., Sarmento-Ribeiro,Ana-B., Costa,Beatriz-P., Matafome,Paulo, Alves,Raquel, Castro-Sousa,Francisco   +8 more
core   +1 more source

Results of 12-month rescue treatment with teduglutide in severely active and parenteral nutrition-dependent Crohn's disease

, 2017
Short bowel syndrome (SBS) is caused by the loss of extensive segments of the small intestine as seen in Crohn’s disease (CD) (1,2) and is characterized by malnutrition; thus, patients with SBS often require parenteral nutrition (PN) (3).
Roberto Caronna, BORGHINI, RAFFAELE, Antonio Picarelli, CORAZZIARI, Enrico Stefano, Enrico S. Corazziari, CARONNA, Roberto, PICARELLI, Antonio, Raffaele Borghini   +7 more
core   +1 more source